Holen Sie sich die Stockscreener-App
0.9235
0.33%
-0.0019
Schlusskurs vom Vortag:
$0.9216
Offen:
$0.94
24-Stunden-Volumen:
1.45M
Relative Volume:
0.80
Marktkapitalisierung:
$360.35M
Einnahmen:
$105.90M
Nettoeinkommen (Verlust:
$-61.49M
KGV:
-4.6831
EPS:
-0.1972
Netto-Cashflow:
$-82.65M
1W Leistung:
-3.30%
1M Leistung:
-18.71%
6M Leistung:
-29.34%
1J Leistung:
-14.94%
1-Tages-Spanne:
$0.91
$0.96
1-Wochen-Bereich:
$0.88
$0.9832
52-Wochen-Spanne:
$0.88
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
Firmenname
Standard Biotools Inc
Sektor
Branche
Telefon
(650) 266-6000
Adresse
50 MILK STREET, BOSTON
Compare LAB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
0.9238 | 359.49M | 105.90M | -61.49M | -82.65M | -0.1972 |
ABT
Abbott Laboratories
|
102.53 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.44 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.60 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.06 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-27 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2024-04-16 | Eingeleitet | TD Cowen | Buy |
| 2024-04-04 | Eingeleitet | Jefferies | Buy |
| 2023-07-12 | Eingeleitet | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Aktie (LAB) Neueste Nachrichten
Can Standard BioTools Inc scale operations efficiently2026 Big Picture & Detailed Earnings Play Strategies - baoquankhu1.vn
Growth Value: Is Standard BioTools Inc impacted by rising rates2026 Catalysts & Safe Capital Preservation Plans - baoquankhu1.vn
Standard BioTools Inc (LAB) Stock Price Quote Today & Current Price Chart - capital.com
Short Interest in Standard BioTools Inc. (NASDAQ:LAB) Declines By 18.5% - MarketBeat
Can Standard BioTools Inc stock double in the next yearCEO Change & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Downgrade Watch: Will Standard BioTools Inc stock hit new highs in YEAR2026 Fed Impact & High Return Trade Opportunity Guides - baoquankhu1.vn
Analysis Recap: Is Standard BioTools Inc impacted by rising rates2026 Sentiment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Earnings Risk: Is Standard BioTools Inc impacted by rising rates2026 Key Lessons & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Standard BioTools (NASDAQ:LAB) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Pullback Watch: Does Standard BioTools Inc have declining or rising EPSMarket Sentiment Summary & Weekly Return Optimization Plans - baoquankhu1.vn
Whale Trades: Can Standard BioTools Inc stock double in the next yearGDP Growth & Safe Entry Momentum Tips - baoquankhu1.vn
Long Focus Capital Management LLC Acquires 1,292,804 Shares of Standard BioTools Inc. $LAB - MarketBeat
Standard BioTools Inc. $LAB Shares Purchased by Mak Capital One LLC - MarketBeat
Standard BioTools Inc. 2025 Annual Report: Market Overview, Innovation, and Regulatory Landscape in Life Sciences Tools - Minichart
Standard BioTools 2025 10-K: Revenue $85.3M, EPS $(0.20) - TradingView
Standard BioTools (NASDAQ: LAB) refocuses on core tools after SomaScan sale - Stock Titan
Tranche Update on Standard BioTools Inc.'s Equity Buyback Plan announced on March 1, 2024. - marketscreener.com
Standard BioTools Inc. $LAB Stake Boosted by Casdin Capital LLC - MarketBeat
Shorts Report: Can Standard BioTools Inc grow without dilution2026 Trading Recap & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Standard BioTools (NASDAQ:LAB) Cut to "Sell" at Wall Street Zen - MarketBeat
Retail Trends: Will Standard BioTools Inc stock hit new highs in YEARWeekly Market Report & Fast Momentum Entry Tips - baoquankhu1.vn
Does Standard BioTools Inc have declining or rising EPSJuly 2025 Chart Watch & Fast Momentum Entry Tips - baoquankhu1.vn
Aug PostEarnings: Should I invest in Standard BioTools Inc before earningsQuarterly Trade Summary & Expert Verified Movement Alerts - baoquankhu1.vn
LAB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LAB Technical Analysis & ETF Price Forecast - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Eli Casdin boosts equity stake in STANDARD BIOTOOLS (LAB) with 52,991 RSUs - Stock Titan
STANDARD BIOTOOLS (LAB) director takes 51,282 RSUs in lieu of $60K cash - Stock Titan
Retail Trends: Is Standard BioTools Inc a strong growth stockJuly 2025 Analyst Calls & Weekly High Return Opportunities - baoquankhu1.vn
Standard BioTools (NASDAQ:LAB) Upgraded to Hold at Wall Street Zen - marketbeat.com
Standard BioTools Inc. (LAB) Stock Analysis: Unveiling a 32% Upside Potential Amidst Challenging Metrics - DirectorsTalk Interviews
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Globus Medical (GMED), Standard BioTools (LAB) and Addus Homecare (ADUS) - The Globe and Mail
Standard BioTools (LAB) Q4 Profit Challenges Longstanding Unprofitable Narrative - Sahm
Standard BioTools Q4 2025 Results: Profit on $23.8M RevenueNews and Statistics - IndexBox
Standard BioTools Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Standard BioTools (LAB) Reports Strong Q4 Revenue Exceeding Expe - GuruFocus
Standard BioTools Inc (NASDAQ:LAB) Surges on Strong Q4 Earnings Beat - ChartMill
STANDARD BIOTOOLS (LAB) CEO has shares withheld to cover RSU tax bill - Stock Titan
Standard BioTools (LAB) SVP disposes shares for tax withholding - Stock Titan
Tax withholding trims Standard BioTools (LAB) CFO share stake - Stock Titan
Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results - Investing News Network
Standard Biotools earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Standard BioTools Details SomaLogic Sale and Profitability Path - TipRanks
LAB Forecasts Revenue Between $80 Million and $85 Million for FY - GuruFocus
Standard BioTools: Q4 Earnings Snapshot - marketscreener.com
Standard BioTools (NASDAQ:LAB) Announces Earnings Results - MarketBeat
Standard BioTools Q4 Earnings Report: What Investors Need to Know - Benzinga
Preview: Standard BioTools's Earnings - Benzinga
LABSTANDARD BIOTOOLS INC Latest Stock News & Market Updates - Stock Titan
Standard BioTools Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Standard BioTools Inc. (LAB) Stock Analysis: Healthcare Innovator Shows 34.78% Potential Upside - DirectorsTalk Interviews
Finanzdaten der Standard Biotools Inc-Aktie (LAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Standard Biotools Inc-Aktie (LAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Casdin Partners Master Fund, L | Director |
Dec 02 '25 |
Buy |
1.42 |
125,000 |
177,512 |
71,875,000 |
| Casdin Partners Master Fund, L | Director |
Dec 03 '25 |
Buy |
1.44 |
75,000 |
108,037 |
71,950,000 |
| Casdin Partners Master Fund, L | Director |
Nov 25 '25 |
Buy |
1.30 |
7,550,000 |
9,838,405 |
71,750,000 |
| Casdin Partners Master Fund, L | Director |
Nov 24 '25 |
Buy |
1.43 |
150,000 |
214,875 |
64,200,000 |
| Casdin Partners Master Fund, L | Director |
Nov 20 '25 |
Buy |
1.30 |
450,000 |
586,260 |
64,050,000 |
| Casdin Partners Master Fund, L | Director |
Nov 19 '25 |
Buy |
1.28 |
350,000 |
448,910 |
63,600,000 |
| Casdin Partners Master Fund, L | Director |
Nov 18 '25 |
Buy |
1.23 |
275,000 |
339,405 |
63,250,000 |
| Casdin Partners Master Fund, L | Director |
Nov 13 '25 |
Buy |
1.20 |
450,000 |
541,395 |
62,500,000 |
| Casdin Partners Master Fund, L | Director |
Nov 14 '25 |
Buy |
1.24 |
250,000 |
309,800 |
62,750,000 |
| Casdin Partners Master Fund, L | Director |
Nov 17 '25 |
Buy |
1.22 |
225,000 |
275,580 |
62,975,000 |
2.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):